ImageneBio reported lower expenses and a narrower third-quarter loss, while giving updates on its lead experimental drug, olevaprubart. The company said its late-stage Phase 2b study in atopic dermatitis remains on track for results in late 2027, and it plans to start a Phase 2 study in alopecia areata by year-end.
- Cash and runway: ImageneBio had $126.6 million in cash, cash equivalents and marketable securities at Sept. 30. It expects that funding to support planned operations into the first quarter of 2028.
- Quarterly expenses and loss: Research and development expenses were $11.3 million, down from $15.2 million a year earlier. General and administrative expenses fell to $6.0 million from $11.0 million. Net loss narrowed to $15.6 million from $24.8 million. Loss per share was 91 cents, compared with $2.91 in the year-earlier quarter.
- Atopic dermatitis trial: The Phase 2b ADAPTIVE study of olevaprubart in moderate-to-severe atopic dermatitis is progressing under an amended protocol. ImageneBio expects topline results in the fourth quarter of 2027. A long-term extension study for patients who complete one year in ADAPTIVE is also progressing.
- Alopecia areata study: The company expects to begin a Phase 2 trial by the end of 2026, with initial data expected in 2028. It plans to draw on clinical operations and investigator relationships developed through its atopic dermatitis program and an earlier alopecia areata proof-of-concept study.
- Drug profile and safety: Olevaprubart, also known as IMG-007, is an investigational antibody that blocks the OX40 pathway. The company describes it as non-T-cell-depleting and engineered to reduce immune-cell killing; its reported half-life is about five weeks. ImageneBio said there have been no cases of Kaposi sarcoma across its clinical trials to date.
- Early research findings: At a 2026 dermatology congress, the company presented exploratory results from its alopecia areata proof-of-concept study. It reported recovery of hair- and follicle-associated genes in scalp samples from treated patients, with no statistically significant changes in OX40 measures that would indicate depletion of OX40-positive cells and no evidence of widespread immune-function disruption. These findings relate to biological markers and do not establish clinical benefit. A separate presentation covered the drug’s pharmacokinetics and the rationale for optimizing exposure in ADAPTIVE.
The near-term development plan centers on the atopic dermatitis readout in late 2027, with alopecia areata adding another potential indication and an earlier expected study start. The cash balance and stated runway extend beyond the anticipated ADAPTIVE topline results, though the company’s estimate covers planned operations only.